Haraguchi, Mizuki
Kiyotani, Kazuma
Tate, Tomohiro
Sakata, Seiji
Sagawa, Ray
Takagi, Satoshi
Nagayama, Satoshi
Takeuchi, Kengo
Takahashi, Kazuhisa
Katayama, Ryohei
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP22ck0106543h0003, JP21ck0106472h0003, JP23ama221201h0002, JP23ama221210h0002, JP23ck0106795h0001)
Ministry of Education, Culture, Sports, Science and Technology (JP20K07399, JP22K18383)
The Princess Takamatsu Cancer Research Fund
Cell Science Research Foundation
Chugai Foundation for Innovative Drug Discovery Science
Nippon Foundation
Takeda Science Foundation
Article History
Received: 17 November 2022
Accepted: 22 May 2023
First Online: 4 June 2023
Declarations
:
: R. Katayama received research funding from Chugai, TAKEDA, Toppan Printing outside the submitted work. K. Kiyotani is a scientific adviser of Cancer Precision Medicine, Inc. Other authors have declared that no conflict of interest exists.
: Informed consent was obtained from all individual participants included in the study. All experiments involving CRC patients were performed in accordance with approved protocols by the Institutional Review Board of Japanese Foundation for Cancer Research (No. 2018-GA-1021). All mice studies were conducted in line with the protocols approved by the Committee for the Use and Care of Experimental Animals of the Japanese Foundation for Cancer Research (No. 10-01-20). The authors affirm that human research participants provided informed consent for publication of this study.